Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Timothy P Hughes

Showing results (111-120 of 205) with videos related to

Pageof 21
Sort By:
British Journal of Cancer|March 14, 2018
Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expressionBarbara J McClure, Susan L Heatley, Chung H Kok, et al.
Blood|April 7, 2006
OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinibDeborah L White, Verity A Saunders, Phuong Dang, et al.
Haematologica|August 11, 2018
Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemiaTimothy P Hughes, Pierre Laneuville, Philippe Rousselot, et al.
Frontiers in Cell and Developmental Biology|May 17, 2021
Polycomb Factor PHF19 Controls Cell Growth and Differentiation Toward Erythroid Pathway in Chronic Myeloid Leukemia CellsMarc García-Montolio, Cecilia Ballaré, Enrique Blanco, et al.
British Journal of Haematology|April 1, 2020
TARGET: a survey of real-world management of chronic myeloid leukaemia across 33 countriesAnna Turkina, Jianxiang Wang, Vikram Mathews, et al.
Blood Advances|May 26, 2019
Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinibChung H Kok, David T Yeung, Liu Lu, et al.
Blood Cancer Journal|April 21, 2022
Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuationShady Adnan Awad, Oscar Brück, Naranie Shanmuganathan, et al.
Blood|May 3, 2002
Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantationCharles G Mullighan, Sue Heatley, Kathleen Doherty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implicationsDevendra K Hiwase, Verity Saunders, Duncan Hewett, et al.
British Journal of Haematology|May 1, 2020
Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cellsYazad D Irani, Amy Hughes, Jade Clarson, et al.
Pageof 21

Showing results (111-120 of 205) with videos related to

Sort By:
Pageof 21
British Journal of Cancer|March 14, 2018
Pre-B acute lymphoblastic leukaemia recurrent fusion, EP300-ZNF384, is associated with a distinct gene expressionBarbara J McClure, Susan L Heatley, Chung H Kok, et al.
Blood|April 7, 2006
OCT-1-mediated influx is a key determinant of the intracellular uptake of imatinib but not nilotinib (AMN107): reduced OCT-1 activity is the cause of low in vitro sensitivity to imatinibDeborah L White, Verity A Saunders, Phuong Dang, et al.
Haematologica|August 11, 2018
Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemiaTimothy P Hughes, Pierre Laneuville, Philippe Rousselot, et al.
Frontiers in Cell and Developmental Biology|May 17, 2021
Polycomb Factor PHF19 Controls Cell Growth and Differentiation Toward Erythroid Pathway in Chronic Myeloid Leukemia CellsMarc García-Montolio, Cecilia Ballaré, Enrique Blanco, et al.
British Journal of Haematology|April 1, 2020
TARGET: a survey of real-world management of chronic myeloid leukaemia across 33 countriesAnna Turkina, Jianxiang Wang, Vikram Mathews, et al.
Blood Advances|May 26, 2019
Gene expression signature that predicts early molecular response failure in chronic-phase CML patients on frontline imatinibChung H Kok, David T Yeung, Liu Lu, et al.
Blood Cancer Journal|April 21, 2022
Epigenetic modifier gene mutations in chronic myeloid leukemia (CML) at diagnosis are associated with risk of relapse upon treatment discontinuationShady Adnan Awad, Oscar Brück, Naranie Shanmuganathan, et al.
Blood|May 3, 2002
Mannose-binding lectin gene polymorphisms are associated with major infection following allogeneic hemopoietic stem cell transplantationCharles G Mullighan, Sue Heatley, Kathleen Doherty, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 19, 2008
Dasatinib cellular uptake and efflux in chronic myeloid leukemia cells: therapeutic implicationsDevendra K Hiwase, Verity Saunders, Duncan Hewett, et al.
British Journal of Haematology|May 1, 2020
Successful treatment-free remission in chronic myeloid leukaemia and its association with reduced immune suppressors and increased natural killer cellsYazad D Irani, Amy Hughes, Jade Clarson, et al.
Pageof 21